An Open Label Phase I Study to Evaluate the Safety and Efficacy of OBP-301 With Pembrolizumab in Patients With Advanced Solid Tumors
Phase of Trial: Phase I
Latest Information Update: 12 Dec 2018
At a glance
- Drugs Pembrolizumab (Primary) ; Telomelysin (Primary)
- Indications Solid tumours
- Focus Adverse reactions
- 03 Dec 2018 Planned primary completion date changed from 1 Jul 2020 to 1 Apr 2020.
- 05 Jun 2018 Trial design presented at the 54th Annual Meeting of the American Society of Clinical Oncology.
- 13 Dec 2017 According to an Oncolys BioPharma media release, first patient has been enrolled.